months after the procedure, the patients revisited the regional hospital for a clinical check-up including an electrocardiogram. No loss to follow-up was reported. The method of outcome evaluation (for example, the use of a questionnaire) was not reported.
Effectiveness results
The rates of death were 1.2% in the non-stented group and 0% in the stented group.
The rates of MIs were 2.4% (non-stented) and 1% (stented). The OR was 0.41 (0.03 -4.5) and the adjusted OR was 0.30 (0.02 -4.4).
The rates of re-PTCA/re-stent were 9.6% (non-stented) and 5% (stented). The OR was 0.49 (0.15 -1.6) and the adjusted OR was 0.73 (0.19 -2.7).
The rates of CABG were 6% (non-stented) and 2% (stented). The OR was 0.32 (0.06 -1.7) and the adjusted OR was 0.48 (0.06 -4).
The rates of death or MI were 3.6% (non-stented) and 1% (stented). The OR was 0.27 (0.03 -2.6) and the adjusted OR was 0.20 (0.01 -2.8).
The rates of MACE were 16.9% (non-stented) and 6.9% (stented). The OR was 0.37 (0.14 -0.96) and the adjusted OR was 0.56 (0.19 -1.7). The difference in MACE was statistically significant, (p=0.04), but did not reach statistical significance when adjusted estimates were calculated. These results were similar to those observed in the EPISTENT study.
Clinical conclusions
The effectiveness analysis showed that the risk of MACE was reduced among patients receiving both the abciximab and stenting procedure, compared with those receiving only abciximab.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used. A cost-consequences analysis was therefore conducted.
Direct costs
Discounting was not performed since the costs were incurred in a short time period. The unit costs were reported separately from the quantities of resources used. The health services included in the economic analysis were for the initial procedure, abciximab, additional stents, hospital stay, revascularisation and CABG. The cost/resource boundary adopted in the study seems to have been the health service. Resource use was estimated using actual data derived from the effectiveness study, while the unit costs were derived from a published study (Serruys et al., see Other Publications of Related Interest). The price year was not reported.
The study confirmed the results of published studies, namely, that the combination of abciximab and stenting may be effective among patients undergoing percutaneous transluminal coronary angioplasty (PTCA) without increasing the costs, not only under the strict patient selection conditions in the clinical trial, but also among patients evaluated in the setting of everyday clinical practice. Although, in the adjusted analysis, the difference in the risk of major cardiac adverse events (MACE) was no longer statistically significant, the authors commented that such a change was due to the small sample size.
CRD COMMENTARY -Selection of comparators
The combination of abciximab and stenting was compared with abciximab alone because the aim of the study was to evaluate the additional value of stenting. You should decide whether abciximab without stenting represents a widely used approach in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness analysis used a prospective cohort study, which was appropriate for the study question. Consecutive patients were selected so there was unlikely to have been any sampling bias, yet it is hard to tell if the study sample was representative of the study population. No power calculations were conducted to evaluate whether or not the sample size was sufficient to detect statistically significant differences in the outcome measures between the groups. Selection bias may well have been a problem since physicians allocated the patients to the intervention and no rationale was discussed for this. The period during which the clinical data were collected was reported, as well the length of follow-up. However, the methods of outcome assessment were not mentioned. No patients were lost to follow-up. There were no highly, statistically significant baseline differences between the groups. However, the statistical significance of the
